In June 2024, a canalicular gel device (Lacrifill, Nordic Pharma) was introduced to the US market, and a recent study has ...

Atsena Therapeutics and Nippon Shinyaku have formed an exclusive licensing agreement for ATSN-101, a gene therapy for Leber ...

FDA clearance of HG202 marks a significant milestone for CRISPR/Cas13 RNA-editing in clinical applications for nAMD. The ...

Peking University researchers have developed a deep learning-based, noninvasive choroidal angiography method that enables ...

A Johns Hopkins study reveals that anti-VEGF treatments for wet AMD may unintentionally elevate ANGPTL4, a protein that ...

FELIQS plans to conduct a Phase 1b/2 study of FLQ-101 (tROPhy-1 study) both in the US and Japan in the first quarter of 2025.

The Valeda Light Delivery System is for the treatment of patients with dry age-related macular degeneration (AMD).

Formosa Pharmaceuticals has announced the completion and top-line results from CPN-303, a phase 3 clinical study of APP13007 ...

They received a $6.4 million grant to support drug development and IND-enabling toxicology studies. Bispecific drugs act as ...

Alfredo Sadun, MD, PhD, is the chief of Ophthalmology at the Doheny Eye Institute of UCLA. At this year's AAO meeting held in ...

Victoria Biousse, MD, from the Emory University in Atlanta, Georgia, shared insights on how ocular imaging in the emergency ...

Dropless cataract surgery eliminates postoperative eye drops, enhancing patient adherence and reducing complications like ...